Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 20, 2019 - Issue 15
Submit an article Journal homepage
5,950
Views
10
CrossRef citations to date
0
Altmetric
Original Research

Efficacy and safety of brexpiprazole as adjunctive treatment in major depressive disorder: overview of four short-term studies

Michael E ThasePerelman School of Medicine, University of Pennsylvania and the Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6403-0861View further author information
ORCID Icon,
Peter ZhangOtsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USAView further author information
,
Catherine WeissOtsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USAORCID Iconhttps://orcid.org/0000-0001-6712-4620View further author information
ORCID Icon,
Stine Rasmussen MeehanH. Lundbeck A/S, Valby, Copenhagen, DenmarkView further author information
&
Mary HobartOtsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USAView further author information
Pages 1907-1916 | Received 23 Nov 2018, Accepted 28 Jun 2019, Published online: 10 Jul 2019

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Soon Nan Wee, Christian Liman, Heidi C Waters, Christy R Houle, Miguel Renteria, Sankha S Mukherjee, Subina Surendran, Joshua Marcovici, Malaak Brubaker, Stine Rasmussen Meehan, Anne de Jong-Laird, A John Rush & Joydeep Sarkar. (2023) Life Engagement Improvement Following Initiation of Brexpiprazole Treatment in Patients with MDD: A Naturalistic, Retrospective Real-World Study. ClinicoEconomics and Outcomes Research 15, pages 195-208.
Read now

Articles from other publishers (9)

Silviya Ralovska, Ivan Koychev, Petar Marinov, Toshi A Furukawa, Benoit Mulsant & Andrea Cipriani. (2023) Brexpiprazole versus placebo or other antidepressive agents for treating depression. Cochrane Database of Systematic Reviews 2023:7.
Crossref
Roger S. McIntyre, François Therrien, Zahinoor Ismail, Stine R. Meehan, Maia Miguelez, Klaus Groes Larsen, Dalei Chen, Erin M. MacKenzie & Michael E. Thase. (2023) Effects of adjunctive brexpiprazole on patient life engagement in major depressive disorder: Post hoc analysis of Inventory of Depressive Symptomatology Self-Report data. Journal of Psychiatric Research 162, pages 71-78.
Crossref
John Cookson & Jonathan Pimm. (2021) Partial agonists of dopamine receptors: mechanisms and clinical effects of aripiprazole, brexpiprazole and cariprazine. BJPsych Advances 29:2, pages 145-150.
Crossref
Gary S. SachsPaul P. YeungLudmyla RekedaArifulla KhanJulie L. AdamsMaurizio Fava. (2023) Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study. American Journal of Psychiatry 180:3, pages 241-251.
Crossref
Martin A. Katzman, François Therrien, Erin M. MacKenzie, Fan Wang, Anne de Jong-Laird & Matthieu Boucher. (2022) Efficacy of adjunctive brexpiprazole on symptom clusters of major depressive disorder: A post hoc analysis of four clinical studies. Journal of Affective Disorders.
Crossref
Catherine Weiss, Stine R. Meehan, T. Michelle Brown, Catherine Gupta, Michael F. Mørup, Michael E. Thase, Roger S. McIntyre & Zahinoor Ismail. (2021) Effects of adjunctive brexpiprazole on calmness and life engagement in major depressive disorder: post hoc analysis of patient-reported outcomes from clinical trial exit interviews. Journal of Patient-Reported Outcomes 5:1.
Crossref
Silviya Ralovska, Ivan Koychev, Franco De Crescenzo, Petar Marinov & Andrea Cipriani. (2021) Brexpiprazole versus placebo or other antidepressive agents for treating depression. Cochrane Database of Systematic Reviews.
Crossref
Sophie R. Vaccarino & Sidney H. Kennedy. 2021. Ketamine for Treatment-Resistant Depression. Ketamine for Treatment-Resistant Depression 33 84 .
C. Weiss, P. Zhang, R.A. Baker, S.R. Meehan, N. Hefting & M. Hobart. (2020) P.331 Brexpiprazole and aripiprazole for the adjunctive treatment of major depressive disorder: post hoc analysis of completion rates in long-term studies. European Neuropsychopharmacology 40, pages S193-S194.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.